BC Innovations | Dec 1, 2016
Product R&D

De-stressing about NASH

With a new use for an old compound, NeuroVive Pharmaceutical AB is positioning its cyclophilin inhibitor as a first-in-class treatment for NASH, adding the liver disease to the company’s repertoire of non-traditional mitochondrial disorders. The...
BC Innovations | Nov 9, 2016
Distillery Therapeutics

Infectious disease

INDICATION: Hepatitis C virus (HCV); HIV/AIDS; coronavirus; viral infection Cell culture and in vitro studies identified phenylpyrrolidine-based inhibitors of CYPA , CYPB and CYPD that could help treat HCV, HIV/AIDS, coronavirus and other viral infections. In...
BC Week In Review | Feb 15, 2016
Clinical News

EDP-494: Phase I started

Enanta began a double-blind, placebo-controlled, dose-escalation, New Zealand Phase I trial to evaluate oral EDP-494 in about 98 healthy volunteers and patients. The first part will evaluate single doses of 50, 100, 200, 400 and...
Items per page:
1 - 3 of 3